



Upinder Singh

Stanford Medicine Professor of Infectious Disease and Professor of Medicine (Infectious Diseases & Geographic Medicine), Emerita
Medicine - Infectious Diseases

Bio

ACADEMIC APPOINTMENTS

- Emeritus Faculty, Acad Council, Medicine - Infectious Diseases
- Member, Bio-X
- Member, Maternal & Child Health Research Institute (MCHRI)
- Member, Wu Tsai Neurosciences Institute

ADMINISTRATIVE APPOINTMENTS

- Associate Chair, Faculty Development, Department of Medicine, (2020-2024)
- Division Chief, Infectious Diseases and Geographic Medicine, (2010-2024)
- Fellowship Co-Director, Division of Infectious Diseases, (2008-2013)

HONORS AND AWARDS

- Member, ASCI (2010)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Fellow, Center for Innovation in Global Health, Stanford University (2015 - present)

PROFESSIONAL EDUCATION

- BS, Ohio State University , Biochemistry (1987)
- MD, Ohio State University , Medicine (1992)

COMMUNITY AND INTERNATIONAL WORK

- Investigating *E. histolytica* genetic diversity, Bangladesh and Georgia

LINKS

- Singh lab website: <http://singhlab.stanford.edu/>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Dr Singh studies the molecular basis of pathogenesis of a medically important parasite, *Entamoeba histolytica*. The work is aimed at understanding the virulence determinants that *E. histolytica* utilizes in causing invasive colonic and hepatic disease. Using a combination of genetic and genomic

approaches we are identifying novel mechanisms that the parasite has developed for invading the human host. Additionally, we study the epidemiological trends of of amebic infection, with the goal of identifying a parasite molecular signature that correlates with invasive potential.

CLINICAL TRIALS

- ACTIV-6: COVID-19 Study of Repurposed Medications, Recruiting
- A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults, Not Recruiting
- ACTIV-2: A Study for Outpatients With COVID-19, Not Recruiting
- COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol, Not Recruiting
- Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients, Not Recruiting
- Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19, Not Recruiting
- Paxlovid for Treatment of Long Covid, Not Recruiting
- Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19, Not Recruiting
- Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19, Not Recruiting
- Understanding the Long-term Impact of COVID-19 in Adults (RECOVER), Not Recruiting

Teaching

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Medicine (Masters Program)
- Microbiology and Immunology (Phd Program)

Publications

PUBLICATIONS

- **Metformin on the Presence of COVID-19 Symptoms 6 Months after Infection: The ACTIV-6 Randomized Clinical Trial.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*
Bramante, C. T., Stewart, T. G., Boulware, D. R., McCarthy, M. W., Gao, Y., Rothman, R. L., Mourad, A., Thicklin, F., Cohen, J. B., Garcia Del Sol, I. T., Shah, N. S., Mehta, M., Quintero Cardona, et al
2026
- **Effect of inhaled interferon- β 1a on SARS-CoV-2 diversity and evolution.** *Microbiology spectrum*
Edelstein, G. E., Sass, T. N., Deo, R., Glover, O. T., Boucau, J., Jaganathan, P., Chew, K. W., Giganti, M. J., Hughes, M. D., Moser, C., Javan, A. C., Fletcher, C. V., McCarthy, et al
2026: e0054126
- **Impact of Sex on Viral Shedding and Symptom Severity During Acute COVID-19.** *Pathogens & immunity*
Kung, E., Deo, R., Choudhary, M. C., Chew, K. W., Evering, T. H., Ignacio, R. B., Jagannathan, P., Flynn, J. P., Regan, J., Moser, C., Giganti, M. J., Hughes, M. D., Ritz, et al
2026; 11 (1): 142-153
- **Viral shedding and symptom severity across populations during acute COVID in the ACTIV-2 study.** *medRxiv : the preprint server for health sciences*
Kung, E., Deo, R., Choudhary, M. C., Chew, K. W., Evering, T. H., Ignacio, R. B., Jagannathan, P., Flynn, J. P., Regan, J., Moser, C., Giganti, M. J., Hughes, M. D., Ritz, et al
2026
- **Long COVID trajectories in the prospectively followed RECOVER-Adult US cohort.** *Nature communications*
Thaweethai, T., Donohue, S. E., Martin, J. N., Hornig, M., Mosier, J. M., Shinnick, D. J., Ashktorab, H., Atieh, O., Blomkalns, A., Brim, H., Chen, Y., Cortez, M. M., Erdmann, et al
2025; 16 (1): 9557

- **Evaluation of Interventions for Cognitive Symptoms in Long COVID: A Randomized Clinical Trial.** *JAMA neurology*
Knopman, D. S., Koltai, D., Laskowitz, D., Becker, J., Charvet, L., Wisnivesky, J., Federman, A., Silverstein, A., Lokhnygina, Y., Piloni, G., Haddad, M., Mahncke, H., Van Vleet, et al
2025
- **BRIDGING DIVISIONS: ASSESSING COHORT-BASED PEER MENTORSHIP FOR EARLY-CAREER FACULTY IN ACADEMIC MEDICINE**
Ye, G., Anand, S., Artandi, M., Collins, W., Go, M., Nguyen, L., Wang, P., Weng, W., Ramchandran, K., Singh, U.
SPRINGER.2025: S490
- **Longitudinal Patient-Reported Outcome Trajectories in Long COVID: Findings From the STOP-PASC Clinical Trial.** *Open forum infectious diseases*
Jagannathan, P., Hedlin, H., Liang, J. W., Shaw, B., Maestri, E., Lin, M., Utz, P. J., Singh, U., Geng, L. N., Bonilla, H.
2025; 12 (10): ofaf634
- **Wearable-derived Sleep Measurements are Associated with Long-COVID in the RECOVER Adult Cohort.** *Research square*
Parthasarathy, S., Brosnahan, S., Sieberts, S., Neto, E., Li, Y., Tummalachera, M., Brown, H., Chow, S., Dunn, J., Haack, M., Islam, S. M., Jacobs-Diggs, M., Jiang, et al
2025
- **Olfactory Dysfunction After SARS-CoV-2 Infection in the RECOVER Adult Cohort.** *JAMA network open*
Horwitz, L. I., Becker, J. H., Huang, W., Akintonwa, T., Hornig-Rohan, M. M., Maranga, G., Adams, D. R., Albers, M. W., Ayache, M., Berry, J., Brim, H., Bryan, T. W., Charney, et al
2025; 8 (9): e2533815
- **Age-Related Changes in the Clinical Picture of Long COVID.** *Journal of the American Geriatrics Society*
Fain, M. J., Horne, B. D., Horwitz, L. I., Thaweethai, T., Greene, M., Hornig, M., Orkaby, A. R., Rosen, C., Ritchie, C. S., Ashktorab, H., Blachman, N., Brim, H., Emerson, et al
2025
- **Single-Cell and Plasma Proteomics Do Not Differentiate Patients With and Without SARS-CoV-2 Antigenemia in Convalescence in a Cohort of 100 Patients.** *Open forum infectious diseases*
Pienkos, S., Swank, Z., Hamlin, R. E., Rao, M., Grant, P., Bonilla, H., Jacobson, K., Jagannathan, P., Singh, U., Walt, D. R., Subramanian, A., Blish, C.
2025; 12 (9): ofaf515
- **Digital Biometric Measures in Long COVID: A Secondary Analysis of the STOP-PASC Randomized Clinical Trial.** *JAMA network open*
Gunturkun, F., Hedlin, H., Botzheim, B., Deng, Y., Bonilla, H., Jagannathan, P., Quach, T. C., Kim, S., Lin, M., O'Riordan, G., Tzeng, H., Adamowicz, L., Demanuele, et al
2025; 8 (8): e2526901
- **Social Determinants of Health and Risk for Long COVID in the U.S. RECOVER-Adult Cohort.** *Annals of internal medicine*
Feldman, C. H., Santacroce, L., Bassett, I. V., Thaweethai, T., Alicic, R., Atchley-Challenner, R., Chung, A., Goldberg, M. P., Horowitz, C. R., Jacobson, K. B., Kelly, J. D., Knight, S., Lutrick, et al
2025
- **Metformin and Time to Sustained Recovery in Adults With COVID-19: The ACTIV-6 Randomized Clinical Trial.** *JAMA internal medicine*
Bramante, C. T., Stewart, T. G., Boulware, D. R., McCarthy, M. W., Gao, Y., Rothman, R. L., Mourad, A., Thicklin, F., Cohen, J. B., Garcia Del Sol, I., T., Ruiz-Unger, J., Shah, N. S., Mehta, et al
2025
- **Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study.** *The Lancet. Infectious diseases*
Ogbuagu, O., Goldman, J. D., Gottlieb, R. L., Singh, U., Shinkai, M., Acloque, G., Fusco, D. N., Gonzalez, E., Kumar, P., Luetkemeyer, A., Lichtman, A., Mozaffarian, A., Koullias, et al
2025
- **Exploring virulence and stress response in Entamoeba histolytica: insights from clinical strains.** *Microbiology spectrum*
Yanagawa, Y., Sharma, M., Izumiyama, S., Singh, U.
2025: e0050625
- **Obeldesivir for Treatment of COVID-19 in Adults and Adolescents Without Risk Factors for Progression to Severe Disease: the OAKTREE Study**

- Ogbuagu, O., Goldman, J. D., Gottlieb, R. L., Singh, U., Shinkai, M., Acloque, G., Fusco, D., Gonzalez, E., Kumar, P. N., Luetkemeyer, A., Lichtman, A., Mozaffarian, A., Koullias, et al
OXFORD UNIV PRESS INC.2025: S1210
- **Role of tRNA-Derived Fragments in Protozoan Parasite Biology.** *Cells*
Sharma, M., Singh, U.
2025; 14 (2)
 - **Sex Differences in Long COVID.** *JAMA network open*
Shah, D. P., Thaweethai, T., Karlson, E. W., Bonilla, H., Horne, B. D., Mullington, J. M., Wisnivesky, J. P., Hornig, M., Shinnick, D. J., Klein, J. D., Erdmann, N. B., Brosnahan, S. B., Lee-Iannotti, et al
2025; 8 (1): e2455430
 - **2024 Update of the RECOVER-Adult Long COVID Research Index.** *JAMA*
Geng, L. N., Erlandson, K. M., Hornig, M., Letts, R., Selvaggi, C., Ashktorab, H., Atieh, O., Bartram, L., Brim, H., Brosnahan, S. B., Brown, J., Castro, M., Charney, et al
2024
 - **2024 Update of the RECOVER-Adult Long COVID Research Index** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*
Geng, L. N., Erlandson, K. M., Hornig, M., Letts, R., Selvaggi, C., Ashktorab, H., Atieh, O., Bartram, L., Brim, H., Brosnahan, S. B., Brown, J., Castro, M., Charney, et al
2024
 - **Identification of two transcription factors that work coordinately to regulate early development inEntamoeba.** *mBio*
Lozano-Amado, D., Singh, U.
2024: e0225024
 - **Sex differences and immune correlates of Long Covid development, symptom persistence, and resolution.** *Science translational medicine*
Hamlin, R. E., Pienkos, S. M., Chan, L., Stabile, M. A., Pinedo, K., Rao, M., Grant, P., Bonilla, H., Holubar, M., Singh, U., Jacobson, K. B., Jagannathan, P., Maldonado, et al
2024; 16 (773): eadr1032
 - **Engaging communities in therapeutics clinical research during pandemics: Experiences and lessons from the ACTIV COVID-19 therapeutics research initiative** *JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE*
Wohl, D. A., Adam, S. J., Gibbs, K. W., Moskowitz, A. L., Ortel, T. L., Singh, U., Jilg, N., Evering, T. H., Fischer, W. A., Taiwo, B. O., Daar, E. S., Lindsell, C. J., Naggie, et al
2024; 8 (1)
 - **Engaging communities in therapeutics clinical research during pandemics: Experiences and lessons from the ACTIV COVID-19 therapeutics research initiative.** *Journal of clinical and translational science*
Wohl, D. A., Adam, S. J., Gibbs, K. W., Moskowitz, A. L., Ortel, T. L., Singh, U., Jilg, N., Evering, T. H., Fischer, W. A., Taiwo, B. O., Daar, E. S., Lindsell, C. J., Naggie, et al
2024; 8 (1): e156
 - **Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial.** *JAMA network open*
Rothman, R. L., Stewart, T. G., Mourad, A., Boulware, D. R., McCarthy, M. W., Thicklin, F., Garcia Del Sol, I. T., Garcia, J. L., Bramante, C. T., Shah, N. S., Singh, U., Williamson, J. C., Rebolledo, et al
2024; 7 (10): e2439332
 - **Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort.** *Annals of internal medicine*
Erlandson, K. M., Geng, L. N., Selvaggi, C. A., Thaweethai, T., Chen, P., Erdmann, N. B., Goldman, J. D., Henrich, T. J., Hornig, M., Karlson, E. W., Katz, S. D., Kim, C., Cribbs, et al
2024
 - **Sex differences and immune correlates of Long COVID development, persistence, and resolution.** *bioRxiv : the preprint server for biology*
Hamlin, R. E., Pienkos, S. M., Chan, L., Stabile, M. A., Pinedo, K., Rao, M., Grant, P., Bonilla, H., Holubar, M., Singh, U., Jacobson, K. B., Jagannathan, P., Maldonado, et al
2024

- **Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial.** *JAMA internal medicine*
Geng, L. N., Bonilla, H., Hedlin, H., Jacobson, K. B., Tian, L., Jagannathan, P., Yang, P. C., Subramanian, A. K., Liang, J. W., Shen, S., Deng, Y., Shaw, B. J., Botzheim, et al
2024
- **Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection (vol 329, pg 1934, 2023)** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*
Thaweethai, T., Jolley, S. E., Karlson, E. W., Levitan, E. B., Levy, B., McComsey, G. A., McCorkell, L., Nadkarni, G. N., Parthasarathy, S., Singh, U., Walker, T. A., Selvaggi, C. A., Shinnick, et al
2024
- **2023: Looking Back and Looking Ahead** *JOURNAL OF INFECTIOUS DISEASES*
Li, J. Z., Clancy, C. J., Singh, U., Sears, C. L.
2024: 619-620
- **Extracellular Vesicles Derived From *Entamoeba histolytica* Have an Immunomodulatory Effect on THP-1 Macrophages.** *Journal of parasitology research*
Chowdhury, D., Sharma, M., Jahng, J. W., Singh, U.
2024; 2024: 7325606
- **Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.** *JAMA*
Stewart, T. G., Rebolledo, P. A., Mourad, A., Lindsell, C. J., Boulware, D. R., McCarthy, M. W., Thicklin, F., Garcia Del Sol, I. T., Bramante, C. T., Lenert, L. A., Lim, S., Williamson, J. C., Cardona, et al
2023
- **Safety and efficacy of inhaled interferon- β 1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial.** *EClinicalMedicine*
Jagannathan, P., Chew, K. W., Giganti, M. J., Hughes, M. D., Moser, C., Main, M. J., Monk, P. D., Javan, A. C., Li, J. Z., Fletcher, C. V., McCarthy, C., Wohl, D. A., Daar, et al
2023; 65: 102250
- **Extracellular Vesicles and Their Impact on the Biology of Protozoan Parasites.** *Tropical medicine and infectious disease*
Sharma, M., Lozano-Amado, D., Chowdhury, D., Singh, U.
2023; 8 (9)
- **The Tomato Brown Rugose Fruit Virus Movement Protein Gene Is a Novel Microbial Source Tracking Marker.** *Applied and environmental microbiology*
Natarajan, A., Fremin, B. J., Schmidtke, D. T., Wolfe, M. K., Zlitni, S., Graham, K. E., Brooks, E. F., Severyn, C. J., Sakamoto, K. M., Lacayo, N. J., Kuersten, S., Koble, J., Caves, et al
2023: e0058323
- **Researching COVID to Enhance Recovery (RECOVER) adult study protocol: Rationale, objectives, and design.** *PloS one*
Horwitz, L. I., Thaweethai, T., Brosnahan, S. B., Cicek, M. S., Fitzgerald, M. L., Goldman, J. D., Hess, R., Hodder, S. L., Jacoby, V. L., Jordan, M. R., Krishnan, J. A., Laiyemo, A. O., Metz, et al
2023; 18 (6): e0286297
- **Transparent Reporting at the Journal of Infectious Diseases.** *The Journal of infectious diseases*
Clancy, C. J., Li, J. Z., Singh, U., Sears, C. L.
2023
- **Diversity and Plasticity of Virulent Characteristics of *Entamoeba histolytica*.** *Tropical medicine and infectious disease*
Yanagawa, Y., Singh, U.
2023; 8 (5)
- **Stress Response in *Entamoeba histolytica* Is Associated with Robust Processing of tRNA to tRNA Halves.** *mBio*
Sharma, M., Zhang, H., Ehrenkauf, G., Singh, U.
2023: e0345022
- **Autoantibodies are highly prevalent in non-SARS-CoV-2 respiratory infections and critical illness.** *JCI insight*

- Feng, A., Yang, E. Y., Moore, A. R., Dhingra, S., Chang, S. E., Yin, X., Pi, R., Mack, E. K., Völkel, S., Geßner, R., Gündisch, M., Neubauer, A., Renz, et al
2023; 8 (3)
- **Challenges in Harnessing Shared Within-Host Severe Acute Respiratory Syndrome Coronavirus 2 Variation for Transmission Inference.** *Open forum infectious diseases*
Walter, K. S., Kim, E., Verma, R., Altamirano, J., Leary, S., Carrington, Y. J., Jagannathan, P., Singh, U., Holubar, M., Subramanian, A., Khosla, C., Maldonado, Y., Andrews, et al
2023; 10 (2): ofad001
 - **Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.** *JAMA*
McCarthy, M. W., Naggie, S., Boulware, D. R., Lindsell, C. J., Stewart, T. G., Felker, G. M., Jayaweera, D., Sulkowski, M., Gentile, N., Bramante, C., Singh, U., Dolor, R. J., Ruiz-Unger, et al
2023
 - **Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection.** *JAMA*
Thaweethai, T., Jolley, S. E., Karlson, E. W., Levitan, E. B., Levy, B., McComsey, G. A., McCorkell, L., Nadkarni, G. N., Parthasarathy, S., Singh, U., Walker, T. A., Selvaggi, C. A., Shinnick, et al
2023
 - **Turning the page: a welcome from the new leadership of the Journal of Infectious Diseases.** *The Journal of infectious diseases*
Sears, C. L., Li, J. Z., Singh, U.
2022; 227 (1): 1-3
 - **Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study.** *eLife*
Hu, Z., van der Ploeg, K., Chakraborty, S., Arunachalam, P. S., Mori, D. A., Jacobson, K. B., Bonilla, H., Parsonnet, J., Andrews, J. R., Holubar, M., Subramanian, A., Khosla, C., Maldonado, et al
2022; 11
 - **Successful recruitment of monolingual Spanish speaking Latinos to university phase II and III outpatient COVID-19 clinical treatment trials in Northern California.** *Contemporary clinical trials*
Levy, V., Bengoa, R. Y., Romero, P. P., Bollyky, J., Singh, U.
2022: 106891
 - **TNF-alpha+ CD4+ T cells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies.** *Cell reports. Medicine*
van der Ploeg, K., Kiro Singh, A. S., Mori, D. A., Chakraborty, S., Hu, Z., Sievers, B. L., Jacobson, K. B., Bonilla, H., Parsonnet, J., Andrews, J. R., Press, K. D., Ty, M. C., Ruiz-Betancourt, et al
2022: 100640
 - **Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*
Holubar, M., Subramanian, A., Purington, N., Hedlin, H., Bunning, B., Walter, K. S., Bonilla, H., Boumis, A., Chen, M., Clinton, K., Dewhurst, L., Epstein, C., Jagannathan, et al
2022
 - **Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection.** *Med (New York, N.Y.)*
Natarajan, A., Zlitni, S., Brooks, E. F., Vance, S. E., Dahlen, A., Hedlin, H., Park, R. M., Han, A., Schmidtke, D. T., Verma, R., Jacobson, K. B., Parsonnet, J., Bonilla, et al
2022
 - **Early immune responses have long-term associations with clinical, virologic, and immunologic outcomes in patients with COVID-19.** *Research square*
Hu, Z., van der Ploeg, K., Chakraborty, S., Arunachalam, P., Mori, D., Jacobson, K., Bonilla, H., Parsonnet, J., Andrews, J., Hedlin, H., de la Parte, L., Dantzer, K., Ty, et al
2022
 - **SARS-CoV-2 Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Kidney Transplant Recipients.** *Kidney360*
Wang, A. X., Busque, S., Kuo, J., Singh, U., Roeltgen, K., Pinsky, B. A., Chertow, G. M., Scandling, J. D., Lenihan, C. R.
2022; 3 (1): 133-143

- **Autoantibodies targeting cytokines and connective tissue disease autoantigens are common in acute non-SARS-CoV-2 infections.** *Research square*
Feng, A., Yang, E., Moore, A., Dhingra, S., Chang, S., Yin, X., Pi, R., Mack, E., Völkel, S., Geßner, R., Gundisch, M., Neubauer, A., Renz, et al
2022
- **Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity.** *Science translational medicine*
Chakraborty, S., Gonzalez, J. C., Sievers, B. L., Mallajosyula, V., Chakraborty, S., Dubey, M., Ashraf, U., Cheng, B. Y., Kathale, N., Tran, K. Q., Scallan, C., Sinnott, A., Cassidy, et al
1800: eabm7853
- **Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses.** *Science translational medicine*
Sievers, B. L., Chakraborty, S., Xue, Y., Gelbart, T., Gonzalez, J. C., Cassidy, A. G., Golan, Y., Prah, M., Gaw, S. L., Arunachalam, P. S., Blish, C. A., Boyd, S. D., Davis, et al
1800: eabn7842
- **Long Term Accuracy of SARS-CoV-2 Interferon-γ Release Assay and its Application in Household Investigation.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*
Murugesan, K., Jagannathan, P., Altamirano, J., Maldonado, Y. A., Bonilla, H. F., Jacobson, K. B., Parsonnet, J., Andrews, J. R., Shi, R. Z., Boyd, S., Pinsky, B. A., Singh, U., Banaei, et al
2022
- **Variation in Severe Acute Respiratory Syndrome Coronavirus 2 Bioaerosol Production in Exhaled Breath.** *Open forum infectious diseases*
Verma, R., Kim, E., Degner, N., Walter, K. S., Singh, U., Andrews, J. R.
2022; 9 (1): ofab600
- **Ponatinib, Lestaurtinib and mTOR/PI3K inhibitors are promising repurposing candidates against Entamoeba histolytica.** *Antimicrobial agents and chemotherapy*
Kangussu-Marcolino, M. M., Singh, U.
2021: AAC0120721
- **New-onset IgG autoantibodies in hospitalized patients with COVID-19.** *Nature communications*
Chang, S. E., Feng, A., Meng, W., Apostolidis, S. A., Mack, E., Artandi, M., Barman, L., Bennett, K., Chakraborty, S., Chang, I., Cheung, P., Chinthrajah, S., Dhingra, et al
2021; 12 (1): 5417
- **RISC in Entamoeba histolytica: Identification of a Protein-Protein Interaction Network for the RNA Interference Pathway in a Deep-Branching Eukaryote.** *mBio*
Zhang, H., Veira, J., Bauer, S. T., Yip, C., Singh, U.
2021: e0154021
- **New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19**
Chang, S., Feng, A., Meng, W., Apostolidis, S., Mack, E., Artandi, M., Barman, L., Bennett, K., Chakraborty, S., Chang, I., Cheung, P., Chinthrajah, S., Dhingra, et al
WILEY.2021: 3202-3205
- **The COVID-19 Outpatient Pragmatic Platform Study (COPPS): Study design of a multi-center pragmatic platform trial.** *Contemporary clinical trials*
Bunning, B., Hedlin, H., Purington, N., Sundaram, V., Kapphahn, K., Weng, Y., Cunanan, K., Maldonado, Y., Singh, U., Khosla, C., O'Hara, R., Nicolls, M., Springman, et al
2021: 106509
- **Standardized and optimized preservation, extraction and quantification techniques for detection of fecal SARS-CoV-2 RNA.** *medRxiv : the preprint server for health sciences*
Natarajan, A., Han, A., Zlitni, S., Brooks, E. F., Vance, S. E., Wolfe, M., Singh, U., Jagannathan, P., Pinsky, B. A., Boehm, A., Bhatt, A. S.
2021
- **Patients with uncomplicated COVID-19 have long-term persistent symptoms and functional impairment similar to patients with severe COVID-19: a cautionary tale during a global pandemic.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*
Jacobson, K. B., Rao, M., Bonilla, H., Subramanian, A., Hack, I., Madrigal, M., Singh, U., Jagannathan, P., Grant, P.

2021

- **Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial.** *Nature communications*
Jagannathan, P. n., Andrews, J. R., Bonilla, H. n., Hedlin, H. n., Jacobson, K. B., Balasubramanian, V. n., Purington, N. n., Kamble, S. n., de Vries, C. R., Quintero, O. n., Feng, K. n., Ley, C. n., Winslow, et al
2021; 12 (1): 1967
- **Standardized preservation, extraction and quantification techniques for detection of fecal SARS-CoV-2 RNA.** *Nature communications*
Natarajan, A., Han, A., Zlitni, S., Brooks, E. F., Vance, S. E., Wolfe, M., Singh, U., Jagannathan, P., Pinsky, B. A., Boehm, A., Bhatt, A. S.
2021; 12 (1): 5753
- **Publisher Correction: Standardized preservation, extraction and quantification techniques for detection of fecal SARS-CoV-2 RNA.** *Nature communications*
Natarajan, A., Han, A., Zlitni, S., Brooks, E. F., Vance, S. E., Wolfe, M., Singh, U., Jagannathan, P., Pinsky, B. A., Boehm, A., Bhatt, A. S.
2021; 12 (1): 7100
- **SARS-CoV-2 subgenomic RNA kinetics in longitudinal clinical samples** *Open Forum Infectious Diseases*
Verma, R., Kim, E., Martinez, G., Jagannathan, ., Rustagi, A., Parsonnet, J., Bonilla, H., Khosla, C., Holubar, M., Subramanian, A., Singh, ., Maldonado, Y., Blish, et al
2021
- **Inflammatory but not respiratory symptoms are associated with ongoing upper airway viral shedding in outpatients with uncomplicated COVID-19.** *Diagnostic microbiology and infectious disease*
Jacobson, K. B., Purington, N., Parsonnet, J., Andrews, J., Balasubramanian, V., Bonilla, H., Edwards, K., Desai, M., Singh, U., Hedlin, H., Jagannathan, P.
2021; 102 (3): 115612
- **Identification of oligo-adenylated small RNAs in the parasite Entamoeba and a potential role for small RNA control.** *BMC genomics*
Zhang, H., Ehrenkauf, G. M., Hall, N., Singh, U.
2020; 21 (1): 879
- **Development of a CRISPR/Cas9 system in Entamoeba histolytica: proof of concept.** *International journal for parasitology*
Kangussu-Marcolino, M. M., Morgado, P., Manna, D., Yee, H., Singh, U.
2020
- **Identification of anisomycin, prodigiosin and obatoclax as compounds with broad-spectrum anti-parasitic activity** *PLOS NEGLECTED TROPICAL DISEASES*
Ehrenkauf, G., Li, P., Stebbins, E. E., Kangussu-Marcolino, M. M., Debnath, A., White, C., Moser, M. S., DeRisi, J., Gisselberg, J., Yeh, E., Wang, S. C., Company, A., Monti, et al
2020; 14 (3)
- **Entamoeba stage conversion: progress and new insights.** *Current opinion in microbiology*
Manna, D. n., Ehrenkauf, G. M., Lozano-Amado, D. n., Singh, U. n.
2020; 58: 62–68
- **The NAD⁺ Responsive Transcription Factor ERM-BP Functions Downstream of Cellular Aggregation and Is an Early Regulator of Development and Heat Shock Response in Entamoeba.** *Frontiers in cellular and infection microbiology*
Manna, D. n., Lozano-Amado, D. n., Ehrenkauf, G. n., Singh, U. n.
2020; 10: 363
- **Interferon-gamma release assay for accurate detection of SARS-CoV-2 T cell response.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*
Murugesan, K. n., Jagannathan, P. n., Pham, T. D., Pandey, S. n., Bonilla, H. F., Jacobson, K. n., Parsonnet, J. n., Andrews, J. R., Weiskopf, D. n., Sette, A. n., Pinsky, B. A., Singh, U. n., Banaei, et al
2020
- **Proinflammatory IgG Fc structures in patients with severe COVID-19** *Nature Immunology*
Chakraborty, S., Gonzales, J., Edwards, K., Mallajosyulla, V., Buzzanco, A. S., Sherwood, R., Buffone, C., Kathale, N., Providenza, S., Xie, M. M., Andrews, J. R., Blish, C. A., Singh, et al
2020

- **Identification of anisomycin, prodigiosin and obatoclax as compounds with broad-spectrum anti-parasitic activity.** *PLoS neglected tropical diseases*
Ehrenkauf, G. n., Li, P. n., Stebbins, E. E., Kangussu-Marcolino, M. M., Debnath, A. n., White, C. V., Moser, M. S., DeRisi, J. n., Gisselberg, J. n., Yeh, E. n., Wang, S. C., Company, A. H., Monti, et al
2020; 14 (3): e0008150
- **Characterization of extracellular vesicles from Entamoeba histolytica identifies roles in intercellular communication that regulates parasite growth and development.** *Infection and immunity*
Sharma, M. n., Morgado, P. n., Zhang, H. n., Ehrenkauf, G. n., Manna, D. n., Singh, U. n.
2020
- **Identification of plicamycin, TG02, panobinostat, lestaurtinib, and GDC-0084 as promising compounds for the treatment of central nervous system infections caused by the free-living amebae Naegleria, Acanthamoeba and Balamuthia.** *International journal for parasitology. Drugs and drug resistance*
Kangussu-Marcolino, M. M., Ehrenkauf, G. M., Chen, E., Debnath, A., Singh, U.
2019; 11: 80–94
- **Functional Characterization of Entamoeba histolytica Argonaute Proteins Reveals a Repetitive DR-Rich Motif Region That Controls Nuclear Localization.** *mSphere*
Zhang, H., Tran, V., Manna, D., Ehrenkauf, G., Singh, U.
2019; 4 (5)
- **Drug treatment algorithms for water-borne parasitic pathogens**
Singh, U.
AMER CHEMICAL SOC.2019
- **Nuclear Factor Y (NF-Y) Modulates Encystation in Entamoeba via Stage-Specific Expression of the NF-YB and NF-YC Subunits.** *mBio*
Manna, D., Singh, U.
2019; 10 (3)
- **An NAD⁺-dependent novel transcription factor controls stage conversion in Entamoeba.** *eLife*
Manna, D., Lentz, C. S., Ehrenkauf, G. M., Suresh, S., Bhat, A., Singh, U.
2018; 7
- **Supporting Research Career Development of Physician-Scientists** *JOURNAL OF INFECTIOUS DISEASES*
Singh, U.
2018; 218: S36–S39
- **High-Throughput Screening of Entamoeba Identifies Compounds Which Target Both Life Cycle Stages and Which Are Effective Against Metronidazole Resistant Parasites** *FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY*
Ehrenkauf, G. M., Suresh, S., Solow-Cordero, D., Singh, U.
2018; 8
- **High-Throughput Screening of Entamoeba Identifies Compounds Which Target Both Life Cycle Stages and Which Are Effective Against Metronidazole Resistant Parasites.** *Frontiers in cellular and infection microbiology*
Ehrenkauf, G. M., Suresh, S., Solow-Cordero, D., Singh, U.
2018; 8: 276
- **Policy Recommendations for Optimizing the Infectious Diseases Physician-Scientist Workforce.** *The Journal of infectious diseases*
Singh, U., Levy, J., Armstrong, W., Bedimo, R., Creech, C. B., Lautenbach, E., Popovich, K. J., Snowden, J., Vyas, J. M., Infectious Diseases Society of America, H. M.
2018; 218 (suppl_1): S49–S54
- **Development of RNA Interference Trigger-Mediated Gene Silencing in Entamoeba invadens.** *Infection and immunity*
Suresh, S., Ehrenkauf, G., Zhang, H., Singh, U.
2016; 84 (4): 964-975
- **Technical advances in trigger-induced RNA interference gene silencing in the parasite Entamoeba histolytica** *INTERNATIONAL JOURNAL FOR PARASITOLOGY*
Khalil, M. I., Foda, B. M., Suresh, S., Singh, U.
2016; 46 (3): 205-212

- **biology: RNA interference, drug discovery, and gut microbiome.** *F1000Research*
Morgado, P., Manna, D., Singh, U.
2016; 5: 2578-?
- **Dimethylated H3K27 Is a Repressive Epigenetic Histone Mark in the Protist *Entamoeba histolytica* and Is Significantly Enriched in Genes Silenced via the RNAi Pathway** *JOURNAL OF BIOLOGICAL CHEMISTRY*
Foda, B. M., Singh, U.
2015; 290 (34): 21114-21130
- **Dimethylated H3K27 Is a Repressive Epigenetic Histone Mark in the Protist *Entamoeba histolytica* and Is Significantly Enriched in Genes Silenced via the RNAi Pathway.** *The Journal of biological chemistry*
Foda, B. M., Singh, U.
2015; 290 (34): 21114-30
- **High Throughput Sequencing of *Entamoeba* 27nt Small RNA Population Reveals Role in Permanent Gene Silencing But No Effect on Regulating Gene Expression Changes during Stage Conversion, Oxidative, or Heat Shock Stress** *PLOS ONE*
Zhang, H., Ehrenkauf, G. M., Manna, D., Hall, N., Singh, U.
2015; 10 (8)
- **A Single RNaseIII Domain Protein from *Entamoeba histolytica* Has dsRNA Cleavage Activity and Can Help Mediate RNAi Gene Silencing in a Heterologous System** *PLOS ONE*
Pompey, J. M., Foda, B., Singh, U.
2015; 10 (7)
- ***Entamoeba histolytica* rhomboid protease 1 has a role in migration and motility as validated by two independent genetic approaches** *EXPERIMENTAL PARASITOLOGY*
Rastew, E., Morf, L., Singh, U.
2015; 154: 33-42
- **High Throughput Sequencing of *Entamoeba* 27nt Small RNA Population Reveals Role in Permanent Gene Silencing But No Effect on Regulating Gene Expression Changes during Stage Conversion, Oxidative, or Heat Shock Stress.** *PloS one*
Zhang, H., Ehrenkauf, G. M., Manna, D., Hall, N., Singh, U.
2015; 10 (8)
- **Regulation of gene expression in the protozoan parasite *Entamoeba invadens*: identification of core promoter elements and promoters with stage-specific expression patterns** *INTERNATIONAL JOURNAL FOR PARASITOLOGY*
Manna, D., Ehrenkauf, G. M., Singh, U.
2014; 44 (11): 837-845
- **Regulation of gene expression in the protozoan parasite *Entamoeba invadens*: identification of core promoter elements and promoters with stage-specific expression patterns.** *International journal for parasitology*
Manna, D., Ehrenkauf, G. M., Singh, U.
2014; 44 (11): 837-845
- **RNAi Pathway Genes Are Resistant to Small RNA Mediated Gene Silencing in the Protozoan Parasite *Entamoeba histolytica*** *PLOS ONE*
Pompey, J. M., Morf, L., Singh, U.
2014; 9 (9)
- **Destabilization domain approach adapted for regulated protein expression in the protozoan parasite *Entamoeba histolytica*.** *International journal for parasitology*
Liu, Y., Singh, U.
2014; 44 (10): 729-735
- **RNAi pathway genes are resistant to small RNA mediated gene silencing in the protozoan parasite *Entamoeba histolytica*.** *PloS one*
Pompey, J. M., Morf, L., Singh, U.
2014; 9 (9)
- **Robust gene silencing mediated by antisense small RNAs in the pathogenic protist *Entamoeba histolytica*.** *Nucleic acids research*
Morf, L., Pearson, R. J., Wang, A. S., Singh, U.
2013; 41 (20): 9424-9437

- **The genome and transcriptome of the enteric parasite *Entamoeba invadens*, a model for encystation.** *Genome biology*
Ehrenkaufer, G. M., Weedall, G. D., Williams, D., Lorenzi, H. A., Caler, E., Hall, N., Singh, U.
2013; 14 (7): R77
- **Regulation of H₂O₂ Stress-responsive Genes through a Novel Transcription Factor in the Protozoan Pathogen *Entamoeba histolytica*** *JOURNAL OF BIOLOGICAL CHEMISTRY*
Pearson, R. J., Morf, L., Singh, U.
2013; 288 (6): 4462-4474
- **Small RNA pyrosequencing in the protozoan parasite *Entamoeba histolytica* reveals strain-specific small RNAs that target virulence genes** *BMC GENOMICS*
Zhang, H., Ehrenkaufer, G. M., Hall, N., Singh, U.
2013; 14
- **Distinct Distal Gut Microbiome Diversity and Composition in Healthy Children from Bangladesh and the United States** *PLOS ONE*
Lin, A., Bik, E. M., Costello, E. K., Dethlefsen, L., Haque, R., Relman, D. A., Singh, U.
2013; 8 (1)
- **Distinct distal gut microbiome diversity and composition in healthy children from Bangladesh and the United States.** *PloS one*
Lin, A., Bik, E. M., Costello, E. K., Dethlefsen, L., Haque, R., Relman, D. A., Singh, U.
2013; 8 (1)
- **The genome and transcriptome of the enteric parasite *Entamoeba invadens*, a model for encystation** *GENOME BIOLOGY*
Ehrenkaufer, G. M., Weedall, G. D., Williams, D., Lorenzi, H. A., Caler, E., Hall, N., Singh, U.
2013; 14 (7)
- **Oxidative stress resistance genes contribute to the pathogenic potential of the anaerobic protozoan parasite, *Entamoeba histolytica*** *INTERNATIONAL JOURNAL FOR PARASITOLOGY*
Rastew, E., Vicente, J. B., Singh, U.
2012; 42 (11): 1007-1015
- **A Detoxifying Oxygen Reductase in the Anaerobic Protozoan *Entamoeba histolytica*** *EUKARYOTIC CELL*
Vicente, J. B., Vy Tran, V., Pinto, L., Teixeira, M., Singh, U.
2012; 11 (9): 1112-1118
- ***Entamoeba histolytica*: a snapshot of current research and methods for genetic analysis** *CURRENT OPINION IN MICROBIOLOGY*
Morf, L., Singh, U.
2012; 15 (4): 469-475
- **Transient and stable transfection in the protozoan parasite *Entamoeba invadens*** *MOLECULAR AND BIOCHEMICAL PARASITOLOGY*
Ehrenkaufer, G. M., Singh, U.
2012; 184 (1): 59-62
- **Nucleus-localized Antisense Small RNAs with 5'-Polyphosphate Termini Regulate Long Term Transcriptional Gene Silencing in *Entamoeba histolytica* G3 Strain** *JOURNAL OF BIOLOGICAL CHEMISTRY*
Zhang, H., Alramini, H., Vy Tran, V., Singh, U.
2011; 286 (52): 44467-44479
- **Antiparasitic Therapy** *MAYO CLINIC PROCEEDINGS*
Kappagoda, S., Singh, U., Blackburn, B. G.
2011; 86 (6): 561-583
- **RNA interference in *Entamoeba histolytica*: implications for parasite biology and gene silencing** *FUTURE MICROBIOLOGY*
Zhang, H., Pompey, J. M., Singh, U.
2011; 6 (1): 103-117
- **Approaches to characterizing *Entamoeba histolytica* transcriptional regulation** *CELLULAR MICROBIOLOGY*
Pearson, R. J., Singh, U.
2010; 12 (12): 1681-1690

- **Downregulation of an *Entamoeba histolytica* Rhomboid Protease Reveals Roles in Regulating Parasite Adhesion and Phagocytosis** *EUKARYOTIC CELL*
Baxt, L. A., Rastew, E., Bracha, R., Mirelman, D., Singh, U.
2010; 9 (8): 1283-1293
- ***Entamoeba histolytica* Genomic Analyses** *ANAEROBIC PARASITIC PROTOZOA: GENOMICS AND MOLECULAR BIOLOGY*
Singh, U., Ehrenkaufner, G. M.
edited by Clark, C. G., Johnson, P. J., Adam, R. D.
2010: 157-73
- **A developmentally regulated Myb domain protein regulates expression of a subset of stage-specific genes in *Entamoeba histolytica*** *CELLULAR MICROBIOLOGY*
Ehrenkaufner, G. M., Hackney, J. A., Singh, U.
2009; 11 (6): 898-910
- **A Pseudouridine Synthase Homologue Is Critical to Cellular Differentiation in *Toxoplasma gondii*** *EUKARYOTIC CELL*
Anderson, M. Z., Brewer, J., Singh, U., Boothroyd, J. C.
2009; 8 (3): 398-409
- **Short hairpin RNA-mediated knockdown of protein expression in *Entamoeba histolytica*** *BMC MICROBIOLOGY*
Linford, A. S., Moreno, H., Good, K. R., Zhang, H., Singh, U., Petri, W. A.
2009; 9
- **Recent insights into *Entamoeba* development: Identification of transcriptional networks associated with stage conversion** *INTERNATIONAL JOURNAL FOR PARASITOLOGY*
Singh, U., Ehrenkaufner, G. M.
2009; 39 (1): 41-47
- ***Entamoeba histolytica* modulates a complex repertoire of novel genes in response to oxidative and nitrosative stresses: implications for amebic pathogenesis** *CELLULAR MICROBIOLOGY*
Vicente, J. B., Ehrenkaufner, G. M., Saraiva, L. M., Teixeira, M., Singh, U.
2009; 11 (1): 51-69
- **Small RNAs with 5' - Polyphosphate Termini Associate with a Piwi-Related Protein and Regulate Gene Expression in the Single-Celled Eukaryote *Entamoeba histolytica*** *PLOS PATHOGENS*
Zhang, H., Ehrenkaufner, G. M., Pompey, J. M., Hackney, J. A., Singh, U.
2008; 4 (11)
- **Transcriptional Regulatory Networks in *Entamoeba histolytica*** *CURRENT DRUG TARGETS*
Ehrenkaufner, G. M., Singh, U.
2008; 9 (11): 931-937
- **New insights into *Entamoeba histolytica* pathogenesis** *CURRENT OPINION IN INFECTIOUS DISEASES*
Baxt, L. A., Singh, U.
2008; 21 (5): 489-494
- **An *Entamoeba histolytica* rhomboid protease with atypical specificity cleaves a surface lectin involved in phagocytosis and immune evasion** *GENES & DEVELOPMENT*
Baxt, L. A., Baker, R. P., Singh, U., Urban, S.
2008; 22 (12): 1636-1646
- **Loss of dsRNA-based gene silencing in *Entamoeba histolytica*: Implications for approaches to genetic analysis** *EXPERIMENTAL PARASITOLOGY*
MacFarlane, R. C., Singh, U.
2008; 119 (2): 296-300
- **Identification of an *Entamoeba histolytica* serine-, threonine-, and isoleucine-rich protein with roles in adhesion and cytotoxicity** *EUKARYOTIC CELL*
MacFarlane, R. C., Singh, U.
2007; 6 (11): 2139-2146

- **Trichostatin A effects on gene expression in the protozoan parasite *Entamoeba histolytica*** *BMC GENOMICS*
Ehrenkaufner, G. M., Eichinger, D. J., Singh, U.
2007; 8
- **Identification of developmentally regulated genes in *Entamoeba histolytica*: insights into mechanisms of stage conversion in a protozoan parasite** *CELLULAR MICROBIOLOGY*
Ehrenkaufner, G. M., Haque, R., Hackney, J. A., Eichinger, D. J., Singh, U.
2007; 9 (6): 1426-1444
- **Functional characterization of spliceosomal introns and identification of U2, U4, and U5 snRNAs in the deep-branching eukaryote *Entamoeba histolytica*** *EUKARYOTIC CELL*
Davis, C. A., Brown, M. P., Singh, U.
2007; 6 (6): 940-948
- **Identification of putative transcriptional regulatory networks in *Entamoeba histolytica* using Bayesian inference** *NUCLEIC ACIDS RESEARCH*
Hackney, J. A., Ehrenkaufner, G. M., Singh, U.
2007; 35 (7): 2141-2152
- **Growth of the protozoan parasite *Entamoeba histolytica* in 5-azacytidine has limited effects on parasite gene expression** *BMC GENOMICS*
Ali, I. K., Ehrenkaufner, G. M., Hackney, J. A., Singh, U.
2007; 8
- **Structure and content of the *Entamoeba histolytica* genome** *ADVANCES IN PARASITOLOGY, VOL 65*
Clark, C. G., Alsmark, U. C., Tazreiter, M., Saito-Nakano, Y., Ali, V., Marion, S., Weber, C., Mukherjee, C., Bruchhaus, I., Tannich, E., Leippe, M., Sicheritz-Ponten, T., Foster, et al
2007; 65: 51-190
- **Impact of intestinal colonization and invasion on the *Entamoeba histolytica* transcriptome** *MOLECULAR AND BIOCHEMICAL PARASITOLOGY*
Gilchrist, C. A., Houpt, E., Trapaidze, N., Fei, Z., Crasta, O., Asgharpour, A., Evans, C., Martino-Catt, S., Baba, D. J., Stroup, S., Hamano, S., Ehrenkaufner, G., Okada, et al
2006; 147 (2): 163-176
- **Identification of differentially expressed genes in virulent and nonvirulent *Entamoeba* species: Potential implications for amebic pathogenesis** *INFECTION AND IMMUNITY*
MacFarlane, R. C., Singh, U.
2006; 74 (1): 340-351
- **Disruption of a locus encoding a nucleolar zinc finger protein decreases tachyzoite-to-bradyzoite differentiation in *Toxoplasma gondii*** *INFECTION AND IMMUNITY*
Vanchinathan, P., Brewer, J. L., Harb, O. S., Boothroyd, J. C., Singh, U.
2005; 73 (10): 6680-6688
- **Coding and noncoding genomic regions of *Entamoeba histolytica* have significantly different rates of sequence polymorphisms: Implications for epidemiological studies** *JOURNAL OF CLINICAL MICROBIOLOGY*
Bhattacharya, D., Haque, R., Singh, U.
2005; 43 (9): 4815-4819
- **Genomic DNA microarrays for *Entamoeba histolytica*: Applications for use in expression profiling and strain genotyping** *2nd EMBO Workshop on Pathogenesis and Amoebiasis*
Macfarlane, R., Bhattacharya, D., Singh, U.
ACADEMIC PRESS INC ELSEVIER SCIENCE.2005: 196-202
- **Transcriptional profiling of *Entamoeba histolytica* trophozoites** *INTERNATIONAL JOURNAL FOR PARASITOLOGY*
MacFarlane, R. C., Shah, P. H., Singh, U.
2005; 35 (5): 533-542
- **Comparative genomic hybridizations of *Entamoeba* strains reveal unique genetic fingerprints that correlate with virulence** *EUKARYOTIC CELL*
Shah, P. H., MacFarlane, R. C., Bhattacharya, D., Matese, J. C., Demeter, J., Stroup, S. E., Singh, U.

2005; 4 (3): 504-515

- **The genome of the protist parasite *Entamoeba histolytica*** *NATURE*
Loftus, B., Anderson, I., Davies, R., Alsmark, U. C., Samuelson, J., Amedeo, P., Roncaglia, P., Berriman, M., Hirt, R. P., Mann, B. J., Nozaki, T., Suh, B., Pop, et al
2005; 433 (7028): 865-868
- **DNA content analysis on microarrays.** *Methods in molecular biology (Clifton, N.J.)*
Singh, U., Shah, P. H., MacFarlane, R. C.
2004; 270: 237-248
- **DNA microarrays in parasitology: strengths and limitations** *TRENDS IN PARASITOLOGY*
Boothroyd, J. C., Blader, I., Cleary, M., Singh, U.
2003; 19 (10): 470-476
- **Investigating amoebic pathogenesis using *Entamoeba histolytica* DNA microarrays** *JOURNAL OF BIOSCIENCES*
Singh, U., Shah, P.
2002; 27 (6): 595-601
- ***Toxoplasma gondii* asexual development: Identification of developmentally regulated genes and distinct patterns of gene expression** *EUKARYOTIC CELL*
Cleary, M. D., Singh, U., Blader, I. J., Brewer, J. L., Boothroyd, J. C.
2002; 1 (3): 329-340
- **Genetic analysis of tachyzoite to bradyzoite differentiation mutants in *Toxoplasma gondii* reveals a hierarchy of gene induction** *MOLECULAR MICROBIOLOGY*
Singh, U., Brewer, J. L., Boothroyd, J. C.
2002; 44 (3): 721-733
- **Identification and characterization of differentiation mutants in the protozoan parasite *Toxoplasma gondii*** *MOLECULAR MICROBIOLOGY*
Matrajt, M., Donald, R. G., Singh, U., Roos, D. S.
2002; 44 (3): 735-47
- **Context-dependent roles of the *Entamoeba histolytica* core promoter element GAAC in transcriptional activation and protein complex assembly** *MOLECULAR AND BIOCHEMICAL PARASITOLOGY*
Singh, U., Gilchrist, C. A., Schaeenman, J. M., Rogers, J. B., Hockensmith, J. W., Mann, B. J., Petri, W. A.
2002; 120 (1): 107-116
- **Diagnosis and management of amebiasis** *CLINICAL INFECTIOUS DISEASES*
Petri, W. A., Singh, U.
1999; 29 (5): 1117-1125
- **Diagnosis and management of amebiasis.** *Clinical Infectious Diseases.*
Singh, U., Petri, Jr, WA
1999: 1117-25
- **The novel core promoter element GAAC in the *hgl5* gene of *Entamoeba histolytica* is able to direct a transcription start site independent of TATA or initiator regions** *JOURNAL OF BIOLOGICAL CHEMISTRY*
Singh, U., Rogers, J. B.
1998; 273 (34): 21663-21668
- **The novel core promoter element GAAC in the *hgl5* gene of *Entamoeba histolytica* is able to direct a transcription start site independent of TATA or *Inr* regions.** *Journal of Biological Chemistry.*
Singh U, Rogers J.
1998: 21663-21668
- **Transcription initiation is controlled by three core promoter elements in the *hgl5* gene of the protozoan parasite *Entamoeba histolytica*** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Singh, U., Rogers, J. B., Mann, B. J., Petri, W. A.
1997; 94 (16): 8812-8817

- **Three conserved cis-acting sequences in the core promoter control gene expression in the protozoan parasite *Entamoeba histolytica*.** *Archives of medical research*
Singh, U., Purdy, J., Mann, B. J., Petri, W. A.
1997; 28: 41-42